Brief: Lundbeck Announces Positive Phase II Proof Of Concept Results With Lu Ag09222 In Migraine Prevention

H Lundbeck A/S

19/04/2023 14:46

April 19 (Reuters) - H Lundbeck A/S  HLUNb.CO :
    * ANNOUNCES POSITIVE PHASE II PROOF OF CONCEPT RESULTS WITH LU AG09222 IN MIGRAINE
PREVENTION
    * HOPE TRIAL MET ITS PRIMARY ENDPOINT IN MIGRAINE PREVENTION
    * PATIENTS TREATED WITH LU AG09222 HAD STATISTICALLY SIGNIFICANTLY GREATER REDUCTION IN
NUMBER OF
MONTHLY MIGRAINE DAYS FROM BASELINE TO WEEKS 1 TO 4 OF TREATMENT VERSUS PLACEBO
    * FULL TRIAL RESULTS ARE NOT YET AVAILABLE
    * LU AG09222 WAS GENERALLY WELL TOLERATED

Source text for Eikon:  ID:nWkr53nndX 
Further company coverage:  HLUNb.CO 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))